Samson Ghilu

Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models

J. Michalek, P. Houghton, D. Guttridge, 2018, Pediatric blood & cancer.

Evaluation of VTP‐50469, a menin‐MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium

P. Houghton, Malcolm A. Smith, D. Phelps, 2020, Pediatric blood & cancer.

The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models

S. Seaman, J. Maris, B. Teicher, 2021, Clinical Cancer Research.

Developing New Agents for Treatment of Childhood Cancer: Challenges and Opportunities for Preclinical Testing

P. Houghton, R. Kurmasheva, Samson Ghilu, 2021, Journal of clinical medicine.

Prospective use of the single-mouse experimental design for the evaluation of PLX038A

P. Houghton, Siyuan Zheng, D. Santi, 2020, Cancer Chemotherapy and Pharmacology.

Evaluation of entinostat alone and in combination with standard‐of‐care cytotoxic agents against rhabdomyosarcoma xenograft models

P. Houghton, Malcolm A. Smith, W. Figg, 2019, Pediatric blood & cancer.

Approaches to identifying drug resistance mechanisms to clinically relevant treatments in childhood rhabdomyosarcoma

P. Houghton, Siyuan Zheng, C. Morton, 2022, Cancer drug resistance.